Combination therapies with bispecific anti-egfr/c-met antibodies and third generation egfr tyrosine kinase inhibitors

A pharmaceutical combination comprising:

• a therapeutically effective amount of an isolated bispecific anti-epidermal growth factor receptor (EGFR)/hepatocyte growth factor receptor (c-Met) antibody;
• and
• a therapeutically effective amount of a compound of formula (I)
• or a pharmaceutically acceptable salt or hydrate thereof.

The pharmaceutical combination of claim 43, wherein the bispecific anti-EGFR/c-Met antibody comprises a first heavy chain (HC1) comprising the amino acid sequence of SEQ ID NO:

• 17, a first light chain (LC1) comprising the amino acid sequence of SEQ ID NO:
• 18, a second heavy chain (HC2) comprising the amino acid sequence of SEQ ID NO:
• 19, and a second light chain (LC2) comprising the amino acid sequence of SEQ ID NO:
• 20.

A pharmaceutical combination comprising:

• a therapeutically effective amount of an isolated bispecific anti-epidermal growth factor receptor (EGFR)/hepatocyte growth factor receptor (c-Met) antibody;
• and
• a therapeutically effective amount of a compound of formula (I)
• or a pharmaceutically acceptable salt or hydrate thereof;
• wherein the bispecific anti-EGFR/c-Met antibody comprises:
• (a) a first domain that binds EGFR comprising the first heavy chain complementarity determining region 1 (HCDR1), the first HCDR2, and the first HCDR3 of the heavy chain variable region (VH) of SEQ ID NO:
• 13 and the first light chain complementarity determining region 1 (LCDR1), the first LCDR2, and the first LCDR3 of the light chain variable region (VL) of SEQ ID NO:
• 14;
• and
• (b) a second domain that binds c-Met comprising the second HCDR1, the second HCDR2, and the second HCDR3 of the VH of SEQ ID NO:
• 15 and the second LCDR1, the second LCDR2, and the second LCDR3 of the VL of SEQ ID NO:
• 16.

A pharmaceutical combination comprising:

• a therapeutically effective amount of an isolated bispecific anti-epidermal growth factor receptor (EGFR)/hepatocyte growth factor receptor (c-Met) antibody;
• and
• a therapeutically effective amount of a compound of formula (I)
• or a pharmaceutically acceptable salt or hydrate thereof;
• wherein the bispecific anti-EGFR/c-Met antibody comprises:
• (a) a first heavy chain comprising the amino acid sequence of SEQ ID NO:
• 17 and a first light chain comprising the amino acid sequence of SEQ ID NO:
• 18;
• and
• (b) a second heavy chain comprising the amino acid sequence of SEQ ID NO:
• 19 and a second light chain comprising the amino acid sequence of SEQ ID NO:
• 20.